Literature DB >> 6817749

Mechanism of inactivation of trypsin by antithrombin.

A Danielsson, I Björk.   

Abstract

General aspects of the mechanism of antithrombin action were elucidated by a comparison of the inactivation of trypsin by antithrombin with the inactivation of coagulation proteinases by the inhibitor. Bovine antithrombin and bovine trypsin were shown to form an inactive equimolar complex. A non-complexed, proteolytically modified form of antithrombin, electrophoretically identical with that formed in the reaction with coagulation proteinases, was also produced in the reaction with trypsin. In the absence of heparin, the inactivation of trypsin by antithrombin was 20 times faster than the inactivation of thrombin; the second-order rate constant was 1.5 x 10(5)m(-1).s(-1) at 25 degrees C and pH 7.4. However, the inhibition of thrombin was accelerated about 30 times more efficiently by small amounts of heparin than was trypsin inhibition. Dissociation of the antithrombin-trypsin complex at pH 7.4 followed first-order kinetics with a half-life for the complex of about 80h at 25 degrees C. The complex was rapidly and quantitatively dissociated at pH 11, resulting in the liberation of a modified two-chain form of the inhibitor, cleaved at the same Arg-Ser bond as in modified antithrombin released from complexes with thrombin, Factor Xa and Factor IXa. This supports the previous proposal that this bond is the active-site bond of antithrombin. Antisera specific for thrombin-modified antithrombin reacted with purified antithrombin-trypsin complex, indicating that the inhibitor was present in the complex in a form immunologically identical with thrombin-modified antithrombin. The results thus suggest a common mechanism, but different kinetics, for the inhibition of trypsin and coagulation proteinases by antithrombin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6817749      PMCID: PMC1153818          DOI: 10.1042/bj2070021

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  40 in total

Review 1.  Biologic actions of heparin.

Authors:  R D Rosenberg
Journal:  Semin Hematol       Date:  1977-10       Impact factor: 3.851

Review 2.  Antithrombin III and heparin.

Authors:  T W Barrowcliffe; E A Johnson; D Thomas
Journal:  Br Med Bull       Date:  1978-05       Impact factor: 4.291

3.  The inhibition of activated bovine coagulation factors X and VII by antithrombin III.

Authors:  J Jesty
Journal:  Arch Biochem Biophys       Date:  1978-01-15       Impact factor: 4.013

4.  Evidence for a heparin-induced conformational change on antithrombin III.

Authors:  G B Villaneuva; I Danishefsky
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

5.  Binding of low-affinity and high-affinity heparin to antithrombin. Ultraviolet difference spectroscopy and circular dichroism studies.

Authors:  B Nordenman; I Björk
Journal:  Biochemistry       Date:  1978-08-08       Impact factor: 3.162

6.  The molecular-weight-dependence of the anti-coagulant activity of heparin.

Authors:  T C Laurent; A Tengblad; L Thunberg; M Höök; U Lindahl
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

7.  Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin.

Authors:  A S Carlström; K Liedén; I Björk
Journal:  Thromb Res       Date:  1977-12       Impact factor: 3.944

8.  Dissociation of complexes and their derivatives formed during inhibition of bovine thrombin and activated factor X by antithrombin III.

Authors:  J Jesty
Journal:  J Biol Chem       Date:  1979-02-25       Impact factor: 5.157

9.  The size and shape of human and bovine antithrombin III.

Authors:  B Nordenman; C Nyström; I Björk
Journal:  Eur J Biochem       Date:  1977-08-15

10.  Binding of heparin to human antithrombin III as studied by measurements of tryptophan fluorescence.

Authors:  R Einarsson; L O Andersson
Journal:  Biochim Biophys Acta       Date:  1977-01-25
View more
  6 in total

1.  Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.

Authors:  Yue Cao; Ake Lundwall; Virgil Gadaleanu; Hans Lilja; Anders Bjartell
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved Amblyomma americanum tick saliva serpin 19.

Authors:  Željko M Radulović; Albert Mulenga
Journal:  Insect Biochem Mol Biol       Date:  2016-11-12       Impact factor: 4.714

3.  Interaction of activated protein C with serpins.

Authors:  J M Hermans; S R Stone
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

4.  Protective effect of antithrombin III in acute experimental pancreatitis in rats.

Authors:  W K Bleeker; J Agterberg; G Rigter; C E Hack; J V Gool
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

5.  A novel serpin with antithrombin-like activity in Branchiostoma japonicum: implications for the presence of a primitive coagulation system.

Authors:  Yeqing Chao; Chunxin Fan; Yujun Liang; Bei Gao; Shicui Zhang
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

6.  Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.

Authors:  Lukas Wettstein; Patrick Immenschuh; Tatjana Weil; Carina Conzelmann; Yasser Almeida-Hernández; Markus Hoffmann; Amy Kempf; Inga Nehlmeier; Rishikesh Lotke; Moritz Petersen; Steffen Stenger; Frank Kirchhoff; Daniel Sauter; Stefan Pöhlmann; Elsa Sanchez-Garcia; Jan Münch
Journal:  J Med Virol       Date:  2022-09-03       Impact factor: 20.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.